Demystified...p53

Journal of Clinical Pathology - Molecular Pathology

Volumn 51, Issue 5, 1998, Pages 248-253

  Darnton, S J ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN; PROTEIN P53;

AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CELL GROWTH; DNA DAMAGE; GENE THERAPY; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0031723620     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.51.5.248     Document Type: Review

References (58)

1. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-8.
2. Hainaut P, Hernandez T, Robinson A, et al. IARC database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res 1998;26:205-13.
3. Donehower LA, Harvey M, Slagle B, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215-21.
4. Lane DP. p53, guardian of the genome. Nature 1992;358: 15-16.
5. Harper JW, Adami GR, Wei N, et al. The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
6. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumour suppression. Cell 1993;75:817-25.
7. Xiong Y, Hannon GJ, Zhang H, et al. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701-4.
8. Vogelstein B, Kinzler KW. p53 function and disfunction. Cell 1992;70:523-6.
9. Hacker G. A sticky business. Curr Biol 1995;5:622-4.
10. Ruley HE. p53 and response to chemotherapy and radiotherapy. In: DeVita VT, Hellman S, eds. Important advances in oncology 1996. Philadelphia: Lippincott-Raven Publishers, 1996:37-56.
11. Bissonnette N, Wasylyk B, Hunting DJ. The apoptotic and transcriptional activities of p53 can be dissociated. Biochem Cell Biol 1997;75:351-8.
12. Cip1 in muscle and other terminally differentiating cells. Science 1995;267:1024-7.
13. Cip1 WAF1 Sd[]. J Pathol 1997;183:134-40.
14. WAF1 Cip1 expression in gestational trophoblastic disease: correlation with clinicopathological parameters, and Ki67 and p53 gene expression. J Pathol 1998;51:159-62.
15. Steller H. Mechanisms and genes of cellular suicide. Science 1995;267:1445-9.
16. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science 1991;253:49-53.
17. Arends MJ, Buckley CH, Wells SM. Aetiology, pathogenesis, and pathology of cervical neoplasia. J Clin Pathol 1998;51:96-103.
18. Momand J, Zambetti GP, Olson DC, et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69: 1237-45.
19. Kraiss S, Quaiser A, Oren M, et al. Oligomerization of oncoprotein p53. J Virol 1988;52:4737-44.
20. Milner J, Metcalf EA. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 1991;65:765-74.
21. Van Meir EG, Polverini PJ, Chazin VR, et al. Release of an inhibition of angiogenesis upon induction of wild-type p53 expression in glioblastoma cells. Nat Genet 1994;8:171-6.
22. Dameron KM, Volpert OV, Tainsky MA, et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin 1. Science 1994;265:1582-4.
23. Ziegler A, Jonanson AS, Leffell DJ, et al. Sunburn and p53 in the onset of skin cancer. Nature 1994;372:773-6.
24. Kushner J, Bradley G, Jordan RCK. Altered p53 expression is probably an early event in oral carcinogenesis. J Pathol 1997;183:418-23.
25. Blount PL, Meltzer SJ, Yin J, et al. Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma. Proc Natl Acad Sci USA 1993;90:3221-5.
26. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
27. Fields S, Jang SK. Presence of a potent activating sequence in the p53 protein. Science 1990;249:1046-9.
28. Jayaraman L, Prives C. Activation of sequence specific DNA binding by short single strands of DNA require the p53 C-terminus. Cell 1995;81:1021-9.
29. Kern SE, Kinzler KW, Bruskin A, et al. Identification of p53 as a sequence specific DNA binding protein. Science 1991; 252:1708-11.
30. Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 1991;88:10124-8.
31. Cooper DN, Krewczak M. The mutational spectrum of single base-pair substitutions causing human genetic disease: patterns and prediction. Hum Genet 1990;85:55-74.
32. Muzeau F, Flejou JF, Potet F, et al. Profile of p53 mutations and abnormal expression of p53 protein in 2 forms of esophageal cancer. Gastroenterol Clin Biol 1996;20:430-7.
33. Greenblatt MS, Bennett WP, Hollstein MC, et al. Mutations in the p53 tumour suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
34. Casson AG, Tammemagi M, Eskandarian S, et al. p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival. J Clin Pathol: Mol Pathol 1998;51:71-9.
35. Orita M, Suzuky Y, Sekiya T, et al. Rapid and sensitive detection of point missense mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989;5:874-9.
36. Hinds PW, Finalay CA, Quartin RS, et al. Mutant p53 DNA clones from human colon carcinomas co-operate with ras in transforming primary rat cells: a comparison of the "hot-spot" mutant phenotypes. Cell Growth Differ 1990;1: 571-80.
37. Gannon JV, Greaves R, Iggo R. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 1990;9: 1595-602.
38. Lane DP, Benchimol S. Oncogene or anti-oncogene? Genes Dev 1990;4:1-8.
39. Tan TH, Wallis J, Levine AJ. Identification of the p53 protein domain involved in the formation of the SV 40 large antigen p53 protein complex. J Virol 1986;659:574-83.
40. Stephen CW, Lane DP. Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library. J Mol Biol 1992;225:577-83.
41. Dowell SP, Ogden JR. The use of antigen retrieval for immunohistochemical detection of p53 overexpression in malignant and benign oral mucosa: a cautionary note. J Oral Pathol Med 1996;25:60-4.
42. Darnton SJ, Jenner K. Microwave irradiation lowers immunohistochemical detection threshold for p53 protein in squamous epithelium from non-neoplastic oesophagus. J Pathol 1998;185:334-5
43. Tanaka H, Shibagaki I, Shimada Y, et al. Characterization of p53 mutations in esophageal squamous cell carcinoma cell lines: increased frequency and different spectrum of mutations from primary tumours. Int J Cancer 1996;65:372-6.
44. McKee PH, Hobos C, Hall PA. Brief report. Antigen retrieval by microwave irradiation lowers immunohistological detection thresholds. Histopathology 1993;23:377-9.
45. Calziolari A, Chiarelli I, Bianchi J, et al. Immunohistochemical vs molecular biology methods. Complementary techniques for effective screening of p53 alterations in head and neck cancer. Am J Clin Pathol 1997;107:7-11.
46. Hollstein MC, Metcalf RA, Welsh JA, et al. Frequent mutations of the p53 gene in human oesophageal cancer. Proc Natl Acad Sci USA 1990;87:9958-61.
47. Reid BJ, Sanchez CA, Blount PL, et al. Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 1993;105:119-29.
48. Mao L, Hruban RH, Boyle JO, et al. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res 1994;54:1634-7.
49. Hruban RH, van der Riet P, Erozan YS, et al. Molecular biology and the early detection of carcinoma of the bladder: the case of Hubert Horatio Humphrey. N Engl J Med 1994; 330:1276-8.
50. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer. Nature 1998;393:229-34.
51. Lavielle JP, Lubin R, Soussi T, et al. Analysis of p53 antibody response in patients with squamous cell carcinoma of the head and neck. Anticancer Res 1996;16:2385-88.
52. Brennan JA, Mao L, Hruban RH, et al. Molecular assessment of histopathologic staging in squamous-cell carcinoma of the head and neck. N Engl J Med 1995;332:429-35.
53. Peyrat J-P, Bonneterre J, Lubin R, et al. Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet 1995;345:621-2.
54. Harriss CC, Hollstein M. Clinical implications of the p53 tumor suppressor gene. N Engl J Med 1993;329:1318-27.
55. Fujiwara T, Grimm EA, Mukhopadhyay T, et al. Induction of chemosensitivity in human lung cancer cells in vivo by adenoviral-mediated transfer of the wild-type p53 gene. Cancer Res 1994;54:2287-91.
56. Peng HQ, Hogg D, Malkin D, et al. Mutations of the p53 gene do not occur in testis cancer. Cancer Res 1993;53: 3574-8.
57. Nguyen KT, Liu B, Uedak K, et al. Transactivation of the human multidrug resistance (MDR1) gene promotor by p53 mutants. Oncol Res 1994;6:71-7.
58. Roth JA, Nguyen D, Lawrence DD, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996;2:985-91.